Humana shares surged following the release of the official 2027 Medicare star ratings by the U.S. health department. The updated scorecard significantly reshapes the financial outlook and bonus payment potential for major health insurers operating within the Medicare Advantage program.
2027 Medicare Star Ratings Highlights
- Humana’s Major Leap: Humana announced that 95% of its Medicare Advantage members are set to be enrolled in plans rated four stars or higher for 2027, marking a sharp increase from 20% in 2026.
- Industry-Wide Benchmarks: According to the U.S. health department, approximately 71% of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or better for 2027.
- Analyst Projections: Financial analysts noted that Humana’s ratings outpace major competitors like UnitedHealth Group and CVS Health (Aetna), positioning the company to secure substantial federal bonus payments.
Understanding Medicare Advantage Star Ratings
The U.S. government evaluates Medicare Advantage and prescription drug plans annually using a star-rating system ranging from one to five stars.
These ratings measure various quality factors, including health-plan quality, drug-plan quality, customer service, and chronic condition management. Plans achieving four stars or higher qualify for lucrative quality bonus payments from the federal government, which insurers typically reinvest into enhanced benefits, reduced out-of-pocket costs, or improved coverage for American seniors.
